Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts That Supports Cancer Progression

Emira Pazolli1,4, Elise Alspach1,4, Agnieszka Milczarek1, Julie Prior2,4, David Piwnica-Worms2,4, and Sheila A. Stewart1,3,4

Abstract

Age is a major risk factor for the development of cancer. Senescent fibroblasts, which accumulate with age, secrete protumorigenic factors collectively referred to as the senescence-associated secretory phenotype (SASP). Here, we examined the molecular mechanisms that control SASP activation, focusing on the known SASP factor osteopontin (OPN). We found that expression of the canonical SASP members interleukin (IL)-6 and IL-8, but not OPN, were dependent upon a persistent DNA damage response (DDR) as evidenced by ATM and NF-kB activation. Treatment with several histone deacetylase (HDAC) inhibitors robustly activated SASP in the absence of DNA breaks, suggesting that DDR-dependent SASP activation occurs in response to chromatin remodeling rather than physical breaks in DNA. In the setting of HDAC inhibition, IL-6 and IL-8 expression remained dependent upon ATM and NF-kB, while OPN expression remained independent of these factors. Further analysis revealed that HDAC1 inhibition was sufficient to induce OPN expression, which is interesting given that loss of HDAC1 expression correlates with increased OPN expression within the stromal compartment of invasive breast cancers. Importantly, fibroblasts treated with HDAC inhibitors promoted tumor growth in vivo. Our findings therefore indicate that HDAC modulation plays an important role in stromal cell activation, with important implications for the use of HDAC inhibitors in the treatment of cancer.

Cancer Res; 72(9); 2251–61. ©2012 AACR.

Introduction

Senescence within incipient tumor cells is a potent tumor suppressive mechanism. Cells undergoing senescence are characterized by a permanent cell-cycle arrest, flattened cellular morphology, increased senescence-associated β-galactosidase (SA-β-gal) activity, and in many instances the appearance of facultative heterochromatin domains known as senescence-associated heterochromatic foci (SAHF; ref. 1). Numerous oncogenic stimuli including activation of cellular oncogenes, persistent DNA damage, and continued cellular proliferation activate senescence (1). Yet the impact of senescence is context dependent. Thus, when activated in an incipient tumor cell, senescence is a potent tumor suppressor that must be bypassed if cells are to complete the transformation process (2). However, when senescence occurs within surrounding stromal cells, those cells function as potent tumor promoters (3, 4).

Extensive microarray analyses have revealed that senescent cells activate a conserved program that is characterized by increased expression of numerous factors including inflammatory cytokines, growth factors, and extracellular matrix (ECM) remodeling enzymes such as matrix metalloproteinases affect branching and migration (6), and other factors including cytokines promote invasion (7, 8). The ability of senescent fibroblasts to influence tumorigenesis has been documented in multiple systems; however, until recently, the underlying molecular mechanisms regulating SASP activation were unknown.

In human cells, both the p53 and Rb pathways function redundantly to activate cellular senescence (9, 10). Abrogation of either pathway is insufficient to bypass senescence following a senescence-inducing stimulus. However, when both the p53 and Rb pathways are inactivated, cells bypass both telomere-driven replicative senescence and stress-induced premature...
senescence, which can be induced by a wide range of cellular stresses. Given the importance of the senescence effector proteins in the activation of senescence, it was hypothesized that their inhibition would result in loss of SASP activation. Surprisingly, when a senescence-inducing dose of DNA damage is delivered to p53/Rb-deficient human cells, these cells continue to divide, yet still activate SASP factors interleukin (IL)-6 and IL-8 (7). Furthermore, when p53 and Rb are abrogated in already senescent, SASP-expressing cells, SASP expression remains (5), indicating that p53/Rb are not required to maintain SASP expression in senescent cells. Together these data indicate that senescent cells robustly express SASP but that the induction of senescence per se is not required to activate or maintain SASP expression.

Investigation into the cellular signaling pathways that activate the SASP indicates that a persistent DNA damage response (DDR) is sufficient to activate some SASP factors. Indeed, signaling downstream of ATM (including NBS1 and Chk2) controls a subset of SASP factors, including IL-6 and IL-8 (7). The mechanisms linking DDR to SASP activation remain unclear but DDR induces chromatin alterations that can impact numerous transcription pathways. Therefore, transcriptional changes that occur in senescent cells may result from specific chromatin modulations. Mounting evidence implicates chromatin remodeling in the establishment of the senescent state. In senescent cells, heterochromatic regions referred to as SAHFs form at E2F promoters and functionally repress cellular proliferation (11). In replicative senescence, histone deacetylase (HDAC) activity diminishes (12) corresponding with an increase in histone acetylation. In addition, a decline in global DNA methylation has been reported in senescent cells [(13) and references therein]. Interestingly, treatment with HDAC inhibitors including sodium butyrate (NaB) or trichostatin A (TSA) induces senescence in some cell types, further supporting the hypothesis that chromatin relaxation plays a causative role in senescence (12, 14).

A role for transcriptional control in the regulation of SASP factors has also been suggested by recent work, particularly for a number of inflammatory factors including IL-6, IL-8, and CXCR2. Transcriptional regulation of such cytokines in other biological settings by NF-κB and CEBPB applies to senescence as well. In fact, these transcription factors occupy the promoters of several cytokines in senescent cells (15, 16). However, it is unknown how these factors are activated in response to senescence-inducing stimuli and subsequently direct transcriptional changes in senescence.

Osteopontin (OPN), also known as secreted phosphoprotein 1, is a multifunctional signaling molecule (17). Originally identified in cancer cells (18), the physiologic function of OPN is linked to matrix integrity and bone maintenance (19). Since its initial identification, OPN has been implicated in every stage of tumorigenesis and is a prognostic factor for several malignancies (20). We previously reported that OPN levels increase in senescent cells and showed that it is a critical mediator of stromal-epithelial interactions in tumorigenesis (4). In addition, OPN expression in the stromal compartment of human skin coincides with senescent markers, raising the possibility that it plays an important role in the early stages of tumorigenesis (21). Despite the importance of senescence-derived OPN, its regulation in senescent cells remains unknown. Here, we report that following senescence-inducing stimuli, OPN upregulation occurs independent of the senescence effector pathways p53 and Rb, similar to what has been shown for other SASP members including IL-6 and IL-8 (5). This finding shows that senescence induction is not a prerequisite for SASP activation following exposure to chronic cellular stress, including treatment with DNA-damaging agents. Further investigation revealed that contrary to the signature SASP members, IL-6 and IL-8, OPN expression is insensitive to NF-κB and ATM signaling. Thus, our results indicate that the SASP is controlled by at least 2 independent transcription programs. Importantly, agents capable of directly perturbing chromatin structure without inducing DNA breaks were potent inducers of SASP, including OPN expression. Specifically, ectopic expression of a dominant negative form of HDAC1 leads to OPN mRNA upregulation. Furthermore, treatment of fibroblasts with HDAC inhibitors led to a significant paracrine stimulation of tumor growth, which suggests that these inhibitors may adversely impact the stromal compartment in the therapeutic setting.

Materials and Methods

Cell lines and treatments

Human foreskin BJ fibroblasts and 293T cells were grown as previously described (4). These cell lines were originally obtained from Dr. Robert Weinberg’s laboratory and were not recently reauthenticated. Human AT fibroblasts (GM09607) were purchased from Coriell Institute, used within 6 months of receipt and grown in minimum essential medium media supplemented with 15% nonheat inactivated FBS (Sigma). WI38 fetal lung fibroblasts were grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% heat-inactivated FBS (Sigma) and transduced with telomerase (pBabe vector with hygromycin selection) and human papilloma virus 16 proteins E6 and E7 [expressed from the LXS vector (22)]. Fibroblasts were mock- or bleomycin sulfate-treated (100 μg/mL Sigma) for 24 hours. After 72-hour serum starvation, RNA was collected with TRI Reagent (Ambion/Applied Biosystems). Cells were incubated with 2 fresh changes of 4 mmol/L sodium butyrate (Sigma) for 72 or 144 hours, 6 μmol/L MS-275 (Santa Cruz Biotechnologies) for 6 days, 3 μmol/L of suberoylanilide hydroxamic acid (SAHA), or vorinostat (Selleck) for 6 days, or 1 mmol/L TSA (Sigma) for 3 days.

Plasmids

The IκBα mutant (IκBα-mut) in a pBabe construct (23) was purchased from Addgene (plasmid 15291). The NF-κB promoter luciferase construct, pκB3-Fluc (Stratagene) and pREL-CMV (Promega) were used in transient transfections. Two short hairpin RNA (shRNA) sequences targeting the human ATM gene (shATM-1: CTCCTACCATCGCCCTTGA; shATM-2: GTATGGTTAAGGAACATCT) were provided in the pLKO.1 plasmid by the Washington University in St. Louis Children’s Discovery Institute and the RNA interference (RNAi)
Institute) at 1:100; Cdk4 (Santa Cruz Biotechnologies) at 1:200; p421, a p53 hybridoma supernatant kindly provided by Edward Seto (Mofit Cancer Center, Tampa, FL.) and was subcloned into the EcoRI/Pacl sites of pBabe-hydrox-3xFLAG vector.

Quantitative PCR

Standard protocol was followed for cDNA and quantitative PCR (qPCR; as previously reported in ref. 4) using the following primers (IDT):

OPN: forward 5'-TTGCAAGCTTCTCAGCCAA-3', reverse 5'-CAAAAGCAAAATCAGTTTCTTCT-3'; glyceraldehyde-3-phosphate dehydrogenase: forward 5'-GATGGCCTTCCGTT-3', reverse 5'-AATGCCAGCCCCAGCTCAAA-3'; IL-6: forward 5'-ACATTCGAGGCCATCTCA-3', reverse 5'-TCACCAGGGAATCTCCTCTC-3'; IL-8: forward 5'-GCTCTGTTGTAAGTGCACTG-3', reverse 5'-TGACCGATTCTTCTTGGAAC-3'; ATM (Taqman; Applied Biosystems, catalog # Hs01112317-g1).

All qPCR results were analyzed with the method reported by Livak and colleagues (26).

Western blot analysis

Fibroblast cell pellets were lysed in buffer containing 50 mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 1 mol/L EDTA, 10% (v/v) glycerol) and protein was quantified by the Bradford Protein Assay (Bio-Rad). The following primary antibodies were used: p421, a p53 hybridoma supernatant kindly provided by Edward Seto (Mofit Cancer Center, Tampa, FL.) and was subcloned into the EcoRI/Pacl sites of pBabe-hydrox-3xFLAG vector.

HDAC1 immunoprecipitation and deacetylase assay

Vehicle and bleomycin-treated fibroblasts were lysed as described (27), and 2 mg of protein was immunoprecipitated with an antibody against HDAC1 (ab7028; Abcam) or a negative control antibody (β-galactosidase, ab616; Abcam) as described (27). HDAC activity was measured with the Fluorode-Lys HDAC Activity Assay Kit (Enzo Life Sciences) per manufacturer’s recommendations.

Expression analysis

Comparison of HDAC1 mRNA levels in normal versus invasive breast cancer-associated stroma was exported from Oncomine (28) as extracted from the study of Finak and colleagues (29). Expression values are log transformed and median centered per array. Differential expression is identified by a permutation test and P values are calculated by t test and corrected for multiple comparisons by the method of false discovery rate (28).

Statistical analysis

Data are presented as the mean ± SD (STDEV) or SEM. Statistical significance was calculated with the Student t test, P < 0.05 was considered significant.

Results

The senescence effector pathways p53 and Rb are not required to activate OPN

Activation of senescence is accompanied by upregulation of protumorigenic factors collectively referred to as the SASP (5). Our previous work revealed that one member of this group, OPN, stimulates preneoplastic keratinocyte growth and is a critical stromal-derived protumorigenic factor in a xenograft model (4). Given the significance of OPN in this model and the importance of the other senescence-secreted proteins, we investigated the regulation of OPN in senescence. We initially turned our attention to the senescence effector and tumor-suppressor proteins p53 and Rb. Importantly, in human cells, inhibition of either the p53 or Rb pathways alone is insufficient to bypass senescence while concomitant abrogation of these pathways allows cells to bypass senescence (30). Despite the importance of p53 and Rb in the activation of senescence, previous work has shown that they actively suppress the activation of some SASP factors including IL-6 and IL-8 (5). However, p53 regulates OPN expression in mouse embryonic fibroblasts, raising the possibility that it plays a role in the regulation of OPN in senescence (31). To investigate the requirement for p53 and Rb activity in senescence-associated OPN regulation, we ectopically expressed a well-characterized dominant negative p53 cDNA (p53-DD; ref. 22) or a cDNA expressing a fusion protein consisting of a mutant form of HDAC1 (EcoRI/ PacI) at 1:100; Cdk4 (Santa Cruz Biotechnologies) at 1:200; p421, a p53 hybridoma supernatant kindly provided by Edward Seto (Mofit Cancer Center, Tampa, FL.) and was subcloned into the EcoRI/Pacl sites of pBabe-hydrox-3xFLAG vector.

SA-βgal staining

SA-βgal staining on cells was carried out as previously described (4).

Xenograft model

All animal procedures were approved by the Washington University School of Medicine Animal Studies Committee. A total of 5 × 106 BJ fibroblasts treated as described above and 5 × 106 HaCaT Fl were injected subcutaneously into the flanks of female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice (NCI-Frederick). In vivo imaging was carried out on days 10 and 12 on an IVIS50 (Caliper; Living Image 3.2, 60 s exposure, binning 8, FOV 12cm, f/stop 1, open filter). For analysis, total photon flux (photons per second) was measured from a fixed region of interest over the xenografts with Living Image 2.6.
that neither abrogation of p53 nor Rb reduced OPN transcripts upon activation of senescence (Fig. 1C). On the contrary, in the absence of p53 or Rb, OPN basal levels in vehicle-treated cells increased (Supplementary Fig. S1B and S1C), and they were further augmented upon bleomycin treatment and the induction of senescence, arguing that p53 and Rb are not only dispensable for the senescence-associated stimulation of OPN expression, but that they suppress it. As previously reported, IL-6 and IL-8 levels were also increased in senescent cells when p53 and Rb function was compromised (Supplementary Fig. S1A; ref. 5), indicating that the p53 and Rb pathways actively suppress a wide range of SASP members.

Previous work had indicated that while SASP factors are robustly activated in senescent cells, the induction of senescence was dispensable for SASP activation (5, 7). We next wished to address whether OPN expression was dependent on SASP activation (5, 7). We next robustly activated in senescent cells, the induction of senescence effector proteins p53 and Rb nor entry into senescence. To determine whether NF-κB activity was required to activate OPN in senescent cells, BJ fibroblasts expressing a control vector or the IκBα-mut were treated with bleomycin. NF-κB can directly activate OPN transcription under certain conditions (33). Therefore, we investigated whether NF-κB activates OPN transcription in senescent cells. NF-κB canonically resides in a complex with IκBα, which sequesters it in the cytoplasm. Upon stimulation, IκBα is phosphorylated and subsequently degraded, allowing NF-κB to translocate to the nucleus where it activates target gene transcription (32). We successfully blocked NF-κB signaling by stably expressing a mutant of IκBα that cannot be phosphorylated (IκBα-mut), thus trapping NF-κB in the cytoplasm (23). To confirm that the mutant was active, we examined its impact on an NF-κB reporter plasmid containing 5 tandem NF-κB–binding elements. In BJ fibroblasts, as expected, we found that expression of the reporter plasmid was inhibited in IκBα-mut cells compared with cells expressing a vector control (Fig. 2A).

To determine whether NF-κB activity was required to activate OPN in senescent cells, BJ fibroblasts expressing a control vector or the IκBα-mut were treated with bleomycin. We found that bleomycin treatment induced robust senescence in the control and IκBα-mut–expressing cells as evidenced by the induction of a flattened morphology and the induction of SA-βgal (Fig. 2B), indicating that this mode of NF-κB inhibition does not abrogate the induction of senescence in these cells. In agreement with previous reports (16), we found that NF-κB activation is essential for the upregulation of IL-6 and IL-8 in senescence (Fig. 2C). Indeed, we found that IκBα-mut cells treated with bleomycin failed to upregulate IL-6 and IL-8. In contrast, OPN levels remained unperturbed in IκBα-mut cells treated with bleomycin (Fig. 2C). Because the expression of the IκBα mutant precedes the exposure to bleomycin, our findings indicate that NF-κB signaling is neither required for the initiation nor maintenance of OPN levels in response to DNA damage. Together these findings also indicate that SASP is regulated by at least 2 distinct transcriptional pathways.

Having established that neither the p53 or Rb pathways nor activation of NF-κB plays a role in OPN regulation following

SASP is controlled by distinct regulatory mechanisms

NF-κB is a master regulator of cytokine production in inflammatory responses (32) and was recently implicated in the transcriptional control of some SASP members, including IL-6 and IL-8 (8, 16). Like IL-6, OPN can participate in cellular responses characterized by chronic inflammation (17), and
bleomycin treatment and SASP activation, we next turned our attention to the putative role of the DDR. Senescence is characterized by a robust and persistent DDR (34) that includes the activation of the ATM kinase, which has been implicated in SASP activation (7). To address whether ATM activation was required for OPN upregulation in senescent cells, we used ATM-specific shRNA constructs to deplete cells of ATM by more than 80% (Fig. 2D). As expected (7), ATM depletion had no impact on the induction of senescence (Fig. 2E) but resulted in a significant reduction in IL-6 and IL-8 levels (Fig. 2F). In contrast, ATM depletion had no impact on OPN expression following bleomycin treatment (Fig. 2F). These results indicate that OPN expression, unlike IL-6 and IL-8, is not controlled by DDR or NF-κB signaling in senescence, but instead is regulated by a distinct mechanism.

HDAC inhibition induces SASP

A wide variety of cellular stresses can induce senescence. Previous work showed agents that impact HDAC activity, including sodium butyrate (NaB) and trichostatin A (TSA), induce senescence or a senescence-like state in the absence of DNA damage (12, 14). These findings raised the possibility that chromatin modulation rather than bona fide DNA breaks were responsible for activation of the SASP. Therefore, we examined whether double-strand DNA breaks were required for SASP expression. BJ fibroblasts were treated with NaB, which...
resulted in a robust cell-cycle arrest and flattened cellular morphology but failed to activate SA-βgal activity (Supplementary Fig. S2). To assess the presence of DNA double-strand breaks, we evaluated levels of γH2AX, a phosphorylated form of the histone variant H2AX that is widely recognized as a marker of double-strand breaks and active DDR (35). As a control for γH2AX induction, we analyzed irradiated cells by Western blot analysis and noted a robust increase in γH2AX as expected. In contrast, NaB treatment did not increase γH2AX levels compared with vehicle-treated cells (Fig. 3A). The comet assay, a sensitive technique used to detect DNA breaks in individual cells (36), corroborated these results (data not shown) in agreement with previous findings (14). Next, we examined OPN mRNA levels and observed robust induction despite the lack of detectable DNA damage (Fig. 3B). In agreement with previous findings, both IL-6 and IL-8 also increased in NaB-treated cells (8). Together these findings indicate that DNA breaks are not required for SASP induction.

HDAC inhibition in tumor cells results in reduced cell growth and tumor cell death. Thus, recent work in xenografts and human clinical trials has focused on the therapeutic potential of HDAC inhibition (37). These findings have led to the approval of one such compound, SAHA or vorinostat, for the treatment of cutaneous T-cell lymphoma, with several other classes of HDAC inhibitors currently in clinical trials (38). Given the putative clinical importance of these inhibitors and our findings with NaB, we tested whether other HDAC inhibitors activated the SASP. Indeed, we found that other HDAC inhibitors including TSA, MS275, and vorinostat similarly increased OPN, IL-6, and IL-8 levels (Fig. 3B). We obtained identical results when we treated primary breast fibroblasts with NaB and vorinostat (Supplementary Fig. S3), indicating that HDAC inhibition also elicits a SASP response in primary stromal cells. Together, these findings raise concern that HDAC inhibitors may impact the tumor microenvironment.

Above we show that the SASP is induced in the absence of DNA double-strand breaks; however, ATM is activated in cells treated with chromatin relaxers (39), raising the possibility that the DDR required to activate IL-6 and IL-8 is initiated by a more general mechanism such as chromatin modulation independently of physical damage. Given that in bleomycin-induced senescence, ATM and NF-κB are required for IL-6 and IL-8 upregulation (Fig. 2), we next investigated whether both ATM and NF-κB were also required to regulate IL-6 and IL-8 in NaB-treated cells. We treated cells that express the IκBα-mut or AT cells (genetically deficient in ATM activity) with NaB as above. Although NaB does not induce DNA double-strand breaks [(14) and data not shown], we found that IL-6 and IL-8 upregulation retained their requirement for both NF-κB and ATM (Fig. 3C and D). In contrast, we observed a robust upregulation of OPN in IκBα-mut–expressing fibroblasts and AT cells following NaB treatment (data not shown). Together these findings indicate that the DNA damage signaling that is required for the upregulation of IL-6 and IL-8 does not
enhancement of HaCATCBR cell growth compared with cells of blasts, there was minimal growth. Significantly, the presence of HDAC inhibition creates a protumorigenic microenvironment

Our findings that HDAC inhibition stimulates the tumor-promoting SASP (Fig. 3B) led us to investigate their impact in vivo. To investigate this, we treated BJ fibroblasts with NaB, which led to the robust upregulation of OPN, IL-6, and IL-8 (Supplementary Fig. S4A) and examined whether these fibroblasts promoted tumor growth in vivo. Similar to our previous report, we found that bleomycin-treated fibroblasts significantly promote preneoplastic HaCaTCBR cell growth when coinfected in xenografts (Fig. 4A and B). When cells were injected in combination with vehicle-treated fibroblasts, there was minimal growth. Significantly, the presence of fibroblasts treated with NaB also led to a substantial enhancement of HaCaTCBR cell growth compared with cells injected with vehicle-treated fibroblasts (Fig. 4A and B), arguing that HDAC inhibition is a potent SASP inducer in vivo. To further corroborate our findings, we tested the only HDAC inhibitor currently used in the clinic—vorinostat. Upon treatment with vorinostat, BJ fibroblasts activated the SASP (Supplementary Fig. S4B) and promoted HaCATCBR cell growth compared with their vehicle counterparts (Fig. 4C and D). Together, our results indicate that HDAC inhibition in the stroma activates a protumorigenic profile and leads to increased tumor growth in vivo.

**HDAC1 inhibition activates OPN**

There are 3 major groups of HDACs (excluding sirtuins) and 18 HDACs are present in the human genome. Most HDAC inhibitors target multiple HDACs; we next examined whether a specific HDAC was critical for OPN activation. A recent study analyzing stromal changes in breast cancer identified OPN as a key component of a stroma-derived prognostic predictor that successfully clustered tumors by clinical outcome (29). Oncogenic-based interrogation of the same data set revealed that HDAC1 levels were significantly ($P < 0.05$) lower in breast cancer–associated stroma compared with normal stroma (Fig. 5A). Given that the SASP is reminiscent of the expression profile observed in CAFs and that the HDAC inhibitors used in our study target HDAC1, we examined whether HDAC1 played an important role in OPN activation.

To determine whether HDAC1 levels changed in vehicle versus bleomycin-treated cells, we examined HDAC1 mRNA levels by qPCR. In agreement with our previous microarray data (4), we observed a decrease in HDAC1 mRNA levels in bleomycin-treated fibroblasts compared with vehicle-treated cells (Fig. 5B). When we immunoprecipitated HDAC1 from vehicle and bleomycin-treated fibroblasts and assayed for deacetylase activity, we observed a consistent decrease in cells treated with bleomycin (Fig. 5C), raising the possibility that loss of HDAC1 activity specifically contributes to OPN activation following bleomycin treatment.

To directly test whether HDAC1 activity was important for the increase in OPN expression, we ectopically expressed a dominant-negative mutant of HDAC1 (HDAC1-DN; ref. 24) in fibroblasts (Supplementary Fig. S5A). Although overexpression of HDAC1-DN significantly reduced cell proliferation, it did not result in growth arrest or SA-$\beta$gal expression (40) and Supplementary Fig. S5B. However, we observed that ectopic expression of HDAC1-DN was sufficient to induce significant upregulation in OPN mRNA levels (Fig. 5D), mirroring the response to treatments with HDAC inhibitors (Fig. 3B).
finding further shows that the induction of the SASP can be decoupled from the induction of senescence. Importantly, this is an HDAC1-specific effect because ectopic expression of an HDAC3 mutant (Supplementary Fig. S4C) did not alter OPN levels (Fig. 5D). Analysis of IL-6 and IL-8 expression in HDAC1-DN–expressing cells revealed that loss of HDAC1 activity was also sufficient to increase IL-8 and to a lesser extent IL-6 while HDAC3-DN had no impact on either IL-6 or IL-8. Together, these findings suggest that chromatin alterations via manipulation of HDAC1 activity impact the regulation of the SASP independent of the activation of senescence.

Discussion

Senescent fibroblasts promote tumorigenesis in multiple models (3, 4). In efforts to understand how this is accomplished, several groups have examined the expression profile of senescent cells and uncovered a signature secretory program enriched in growth factors, cytokines, and proteases termed the SASP (4, 5, 15, 16). Specific SASP components have been directly implicated in senescent stromal-promoted tumorigenesis (4, 6, 8, 15). However, it is still unclear how the SASP is activated. Initial findings showed that the transcription factors NF-xB and C/EBPβ directly bind the promoters of some of the inflammatory cytokines expressed in senescent cells (8, 15, 16). In addition, the DDR was identified as an upstream SASP inducer (7). Indeed, the above-mentioned transcription factors can be activated in response to DNA damage (41, 42), although the mechanism of activation in senescence is not known. Using OPN as a surrogate for SASP regulation, we found that the SASP is not characterized by a single transcriptional axis, but is instead controlled by at least 2 independent signaling cascades both of which may be activated in response to chromatin changes.

OPN impacts a vast array of signaling pathways, hence its transcription is governed by multiple mechanisms in a tissue- and context-dependent manner (17). We show that following a senescence-inducing dose of bleomycin, OPN expression is not controlled by p53, Rb, or NF-xB (31, 33). The lack of p53 and Rb involvement is in agreement with previous work showing that these essential senescence effector pathways are dispensable for activation of the SASP factors IL-6 and IL-8 (5). Furthermore, our work shows that OPN, like other SASP factors including IL-6 and IL-8, is expressed in cells that are unable to senesce due to abrogation of the p53 and Rb pathways. This finding is significant because it shows that while senescent cells express SASP factors, the induction of senescence is not required to activate the SASP. Thus, SASP activation may occur in a wide variety of stromal cells undergoing cellular stress. It is interesting to note that the SASP is highly reminiscent of the expression profile observed in CAF, which like senescent cells stimulate tumor formation in xenograft models (43).

This work and that of others show p53 and Rb are uniformly dispensable for SASP expression, yet it is clear that SASP regulation is complex and several distinct mechanisms drive expression of specific SASP factors. Indeed, we show that although NF-xB directly activates IL-6 and IL-8 (Fig. 2 and data not shown), it is not required for OPN upregulation in senescence (Fig. 2 and data not shown). Similarly, ATM knockdown has a profound effect on IL-6 and IL-8 expression, yet OPN increases to the same levels as in control cells (Fig. 2). Together, these results indicate that IL-6 and IL-8 are activated by the DDR and NF-xB as has been shown (7, 8), and OPN is not. Therefore, it is reasonable to speculate that subsets of SASP are
Regulation of Stroma-Derived OPN

Regulated by discrete signaling pathways. In fact, the SASP is defined by distinct classes of proteins such as growth factors, mitogens, and extracellular remodeling enzymes (4) whose activation may be governed by several mechanisms. Indeed, our work shows that OPN regulation is distinct from the inflammatory cytokines IL-6 and IL-8 (15, 16). Discovery of putative activators of OPN and whether they control the expression of other proteins belonging to the ECM core of the SASP is the subject of ongoing work (4).

Despite the fact that IL-6 and IL-8 are regulated independently of OPN, following the induction of senescence, all 3 factors increase at the mRNA level, arguing that there must be a common inducer of SASP. Our work shows that ATM and NF-kB are not the sole SASP regulators, raising the possibility that an upstream stimulus initiates multiple signaling cascades. Our experiments with HDAC inhibitors show that in the absence of DNA breaks (as measured by H2AX phosphorylation and comet assays [see Fig. 3 and (14)], the SASP is still activated. Interestingly, ATM and NF-kB are still required for the upregulation of IL-6 and IL-8 (Fig. 3) in HDAC inhibitor-induced SASP, thus lending additional support to the argument that DNA damage signaling, but not breaks per se, activates the SASP. HDAC inhibition modifies the chromatin by inducing hyperacetylation of histone and nonhistone proteins (44), resulting in sustained transcriptional changes (44). The data presented here fit a model wherein ATM activation upon bleomycin and NaB treatment occurs in response to chromatin alteration. It is known that DNA breaks induce changes in the surrounding chromatin, which facilitates signaling and repair; conversely, chromatin modifications trigger the DNA damage checkpoint (45). Indeed, because treatment with an HDAC inhibitor activates ATM (39), it is plausible that chromatin relaxation in senescence induces ATM activation and subsequent IL-6 and IL-8 expression.

Although it is unclear how chromatin changes are instituted and maintained in senescence, there is ample evidence for their presence (11, 46). It is conceivable that widespread chromatin modifications impact promoter activity globally. However, only 2% of the genes are differentially regulated in senescence (4) making this unlikely. Furthermore, specific transcription factors (e.g., NF-kB and C/EBPβ) are required for expression of some SASP factors, pointing to a regulated mechanism of expression. Finally, our results show that only specific chromatin modifiers impact OPN expression. Specifically, inhibition of HDAC1 but not HDAC3, upregulates OPN, IL-6, and IL-8 mRNA levels. Furthermore, we observe a reduction in HDAC1 levels and activity in senescent cells compared with their vehicle-treated counterparts. Together these data argue that HDAC1 containing complexes drive chromatin alterations that then drive OPN expression. HDACs role in transcriptional regulation is not limited to SASP. Indeed, HDAC1 inhibition results in an altered transcriptional profile in HGPS cells (27).

In addition, HDAC1 is decreased in breast cancer stroma [Fig. 5A and (29)], which also undergoes profound transcriptional changes that alter the microenvironment and contribute to tumorigenesis. What initiates the changes in chromatin in these different biological settings is currently unknown and the triggers are likely to vary depending on the biological context. It is known that HDAC1 binds Rb (47) and interestingly, individual inhibition of either Rb or HDAC1 leads to marked upregulation of OPN mRNA levels (Figs. 1 and 5), raising the possibility that in nonsenescent cells HDAC1 complexes occupy SASP promoters and actively repress transcription, but upon senescence induction, they translocate preferentially to E2F targets (47). It remains to be determined whether the Rb-HDAC1 complex is targeted to the promoters of OPN and other SASP members or whether it controls upstream regulators.

Our results add an additional layer of complexity to HDACs and their putative involvement in the tumor microenvironment. Recently, significant effort has been invested in designing HDAC inhibitors as anticancer agents leading to the approval of 1 compound, vorinostat (also known as SAHA), for the treatment of cutaneous T-cell lymphoma (48) and several others currently in clinical trials (49). Most studies focus on the antiproliferative or apoptotic effects of these reagents on tumor cells and report a minimal impact on normal cells (48, 50, 51). Our studies suggest that the impact of HDAC inhibition on normal cells is quite different. When normal cells, including fibroblasts are treated with HDAC inhibitors they are relatively resistant to apoptosis (52) but enter a senescence-like state (14). Moreover, regardless of the effect on cell-cycle progression, all the HDAC inhibitors we tested (Fig. 3B) robustly upregulate SASP expression and promote tumor growth in vivo in a paracrine fashion (Fig. 4). The half-life of the HDAC inhibitors used in the clinic is relatively short (52), limiting the therapeutic window for solid malignancies (53). However, the molecular responses as measured by overall hyperacetylation are sustained following treatment with HDAC inhibitors. Our results indicate that the transcriptional changes associated with HDAC inhibitor treatment are maintained in normal fibroblasts, and previous studies have shown that the SASP is a chronic response (7). Therefore, it will be important to assess sustained molecular changes in the stroma that may lead to increased tumor formation following HDAC therapy. Our work underscores the importance of examining the tumor microenvironment when analyzing the profile of therapeutic agents.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Dr. Cindy Malone and the Stewart laboratory for helpful discussions; Daniel Teadsy, Megan Rubland, and Hayley Moore for critical reviews of the manuscript; Dr. Joseph Roti Roti and Robert Vanderweil for carrying out the COMET assay; and Adnan Ebrahimali for invaluable help with bioinformatic analysis.

Grant Support

This work was supported by the NIH Molecular Oncology Training grant T32 CA113275 (E. Pazolli), NIH Cellular Biochemical and Molecular Sciences Pre-doctoral Training grant T32 GM00767-35 (E. Alspach), the HHMI Medical Research Fellows Program (A. Milczarek), Molecular Imaging Center P50 CA94056 (D.P. Worms), and NIH 5 R01 CA130919 (S.A. Stewart).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 17, 2011; revised February 7, 2012; accepted March 6, 2012; published OnlineFirst March 15, 2012.

www.aacjournals.org

Cancer Res; 72(9) May 1, 2012

2259

Downloaded from cancerres.aacrjournals.org on April 9, 2017. © 2012 American Association for Cancer Research.
References

Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts That Supports Cancer Progression

Ermira Pazolli, Elise Alspach, Agnieszka Milczarek, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-3386

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/03/15/0008-5472.CAN-11-3386.DC1

Cited articles
This article cites 52 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/9/2251.full.html#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
/content/72/9/2251.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.